Jasper Therapeutics (JSPR) reported preliminary data from the ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria or symptomatic dermographism. The company said 14 of 15 participants enrolled in both dose cohorts of the study achieved a clinical response within the 6-week preliminary analysis period following administration. In the 120mg dose cohort, 83% experienced a complete response. Briquilimab was well tolerated in the study.
Jasper has obtained regulatory clearance to enroll a 180mg dose cohort in the SPOTLIGHT study. The company expects to present full data from the SPOTLIGHT study in the first half of 2025.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.